In the article we present today about Proxibarbital we will address a topic of great relevance today, which will undoubtedly capture the attention of our readers. Whether we are talking about Proxibarbital as an emblematic figure, a historical event, a social phenomenon or any other aspect of interest, we seek to provide a complete and detailed vision that allows us to fully understand its importance and impact on society. Throughout this article, we will explore different aspects related to Proxibarbital, analyzing its origins, evolution, implications and possible future projections. We are sure that the information presented in this article will be very useful for all those interested in expanding their knowledge about Proxibarbital.
| Clinical data | |
|---|---|
| Other names | Proxibarbital, Centralgol, Ipronal, 5-Allyl-5-(β-hydroxypropyl)barbituric acid |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.018.004 |
| Chemical and physical data | |
| Formula | C10H14N2O4 |
| Molar mass | 226.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Proxibarbital (Ipronal) is a barbiturate derivative synthesized in 1956. It has anti-anxiety properties and is, in contrast to most barbiturates, almost without hypnotic action.[1] It was also used in the treatment of migraine headaches in a similar manner to butalbital.[2]
Valofane isomerizes to proxibarbal in vivo.[3]
{{cite book}}: CS1 maint: location missing publisher (link)